What type of study is this?

This is a Cohort Study study (also classified as: Validation Study).

What question did this study set out to answer?

To describe late cytopenias and their impact on survival outcomes in patients with relapsed refractory large B-cell lymphoma receiving CAR T-cell therapy.

December 8, 2025BloodOpen Access

Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy

View Full Paper

Ask AI

Bookmark

Authors

HVHarjot VohraPrincess Margaret Cancer Centre EAEshetu G. AtenafuUniversity Health Network JKJohn KuruvillaUniversity of Toronto

Discussion

Member takes

Implication

Retrospective analysis showed persistent cytopenias in R/R LBCL patients post CAR T-cell therapy, indicating the CAR HEMATOTOX score's predictive value for outcomes.

Key Points

To describe late cytopenias and their impact on survival outcomes in patients with relapsed refractory large B-cell lymphoma receiving CAR T-cell therapy.
Single-centre, retrospective analysis of patients with R/R LBCL who received anti-CD19 CAR T-cell therapy from June 2020 to April 2024.
Evaluated frequency of persistent cytopenias beyond 30 days and validated CAR HEMATOTOX score at 3, 6, and 12 months.
Cytopenias graded by CTCAEv.5 and ICAHT grading, with patients censored at time of death, progression, or last follow-up.
98% of patients had any grade cytopenias at 1 month post CAR T infusion, with high rates of anemia (94.6%) and neutropenia (62.8%).
At 3 months, 88% experienced any grade cytopenias; by 6 months, ≥G3 anemia and thrombocytopenia were noted in 5% and 11%, respectively.
High CAR-HT score predictive of ICAHT at 3 months, with association to worse overall survival and progression-free survival.

Cite This Study

Vohra et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e27a https://doi.org/10.1182/blood-2025-5505

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis showed persistent cytopenias in R/R LBCL patients post CAR T-cell therapy, indicating the CAR HEMATOTOX score's predictive value for outcomes.

Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider